Effective 1 de novembro, 2021, for commercial products, criteria used for medical necessity review of the following tests can be found in this medical policy and will no longer be in the online authorization tool: Breast Cancer Index, Prosigna, MammaPrint and EndoPredict. Please refer to the draft medical policy for coding and other details here.